Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 021992

Expand all

PRISTIQ (DESVENLAFAXINE SUCCINATE)
EQ 25MG BASE
Marketing Status: Prescription
Active Ingredient: DESVENLAFAXINE SUCCINATE
Proprietary Name: PRISTIQ
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: EQ 25MG BASE
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N021992
Product Number: 003
Approval Date: Aug 20, 2014
Applicant Holder Full Name: PF PRISM CV
Marketing Status:  Prescription
Patent and Exclusivity Information
PRISTIQ (DESVENLAFAXINE SUCCINATE)
EQ 50MG BASE
Marketing Status: Prescription
Active Ingredient: DESVENLAFAXINE SUCCINATE
Proprietary Name: PRISTIQ
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: EQ 50MG BASE
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N021992
Product Number: 001
Approval Date: Feb 29, 2008
Applicant Holder Full Name: PF PRISM CV
Marketing Status:  Prescription
Patent and Exclusivity Information
PRISTIQ (DESVENLAFAXINE SUCCINATE)
EQ 100MG BASE
Marketing Status: Prescription
Active Ingredient: DESVENLAFAXINE SUCCINATE
Proprietary Name: PRISTIQ
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: EQ 100MG BASE
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N021992
Product Number: 002
Approval Date: Feb 29, 2008
Applicant Holder Full Name: PF PRISM CV
Marketing Status:  Prescription
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English